Development of a Polynucleotide Vaccine from Melanoma Antigen Recognized by T Cells-1 and Recombinant Protein from Melanoma Antigen Recognized by T Cells-1 for Melanoma Vaccine Clinical Trials

Journal of Immunotherapy

Volumn 23, Issue 3, 2000, Pages 379-386

  Lee, Seung won ^a   Li, Hui ^a   Strong, Theresa V ^a   Moore, Susan E ^a   Conry, Robert M ^a  

^a University of Alabama at Birmingham Heersink School of Medicine   (United States)

Author keywords

Clinical trial; MART 1 DNA vaccine; Polynucleotide vaccine; Recombinant protein

Indexed keywords

CANCER VACCINE; MELANOMA ANTIGEN; POLYNUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNIZATION; DRUG SAFETY; FEMALE; IMMUNE RESPONSE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; VACCINE PRODUCTION;

ANIMALS; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; IMMUNOHISTOCHEMISTRY; MELANOMA; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; PLASMIDS; RECOMBINANT PROTEINS; VACCINES, DNA;

EID: 0034110597     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200005000-00011     Document Type: Article

References (27)

1. Kawakami Y, Eliyahu S, Delgaldo CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994; 91:3515-9.
2. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanoma. J Exp Med 1994; 180:35-42.
3. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180:347-52.
4. Sensi M, Traversari C, Radrizzani M, et al. Cytotoxic T lymphocyte clones from different patients display limited T-cell receptors variable gene usage in HLA-A2 restricted recognition of Melan/MART-1 melanoma antigen. Proc Natl Acad Sci U S A 1995; 92:5674-8.
5. Rivoltini L, Loftus DJ, Barracchini K, et al. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. J Immunol 1996; 156:3882-91.
6. Romero P, Gervois N, Schneider J, et al. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted melan-A/MART-1 antigenic peptide in melanoma. J Immunol 1997; 159:2366-74.
7. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995; 154:2257-65.
8. Marincola F, Rivoltini L, Salgaller M, et al. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. J Immunotherapy 1996; 19:266-77.
9. Kawakami Y, Robbins PF, Wang RF, Rosenberg SA. Identification of melanoma antigens recognized by T lymphocytes and their use in the immunotherapy of cancer. Principles and Practice of Oncology: Updates. 1996; 10:1-20.
10. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with peptide from MART-1/MelanA. Can J Sci Am 1997; 3:37-44.
11. Conry RM, LoBuglio AF, Curiel DT. Polynucleotide-mediated immunization therapy of cancer. Semin Oncol 1996; 23:135-47.
12. Wang B, Boyer J, Srikantan V, et al. DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates. DNA Cell Biol 1993; 12:799-805.
13. Ulmer JB, Deck RR, DeWitt CM, et al. Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vaccine 1994; 12:1541-4.
14. Conry RM, LoBuglio AF, Loechel F, et al. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther 1995; 2:59-65.
15. Conry RM, LoBuglio AF, Loechel F, et al. A carcinoembryonic antigen polynucleotide vaccine for human clinical use. Cancer Gen Ther 1995; 2:33-8.
16. Irvine KR, Rao JB, Rosenberg SA, Restifo NP. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 1996; 156:238-45.
17. Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 1996; 2:1038-41.
18. Conry RM, White SA, Fultz PN, et al. Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen. Clin Cancer Res 1997; 4:2903-12.
19. Conry RM, Strong TV, White SA, et al. Phase I trial of polynucleotide immunization to carcinoembryonic antigen in patients with metastatic colorectal cancer [Abstract O-126]. Cancer Gene Therapy 1997; 4:S49.
20. Smith DB, Johnson KS. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 1988; 67:31-40.
21. Kawakami Y, Battles JK, Kobayashi T, et al. Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. J Immunol Meth 1997; 202:13-25.
22. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother 1996; 19:81-4.
23. Kim CJ, Prevette T, Cormier J, et al. Dendritic cells infected with poxviruses encoding MART-1/Melan-A sensitize T lymphocytes in vitro. J Immunother 1997; 20:276-86.
24. Reeves ME, Royal RE, Lam JS, Rosenberg SA, Hwu P. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 1996; 56:5672-7.
25. Chen YT, Stockert E, Jungbluth A, et al: Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci USA 1996; 93:5915-9.
26. Ribas A, Butterfield LH, McBride WH, et al: Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res 1997; 57:2865-9.
27. Zhai Y, Yang JC, Spiess P, et al: Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother 1997; 20:15-25.